Dental materials polymerizable by photo-induced ring-opening metathesis polymerization of cyclic olefins

Dental material being polymerizable by ring-opening metathesis polymerization comprising (i) at least one ruthenium complex bearing at least one N-heterocyclic carbene ligand or precursors which generate a ruthenium complex bearing at least one N-heterocyclic carbene ligand in situ; and (ii) at least one cyclic olefin capable of metathesis.
This invention relates to polymerizable compositions which can be polymerized by visible-light-induced ring-opening metathesis polymerization. These compositions are particularly useful as dental materials for operative and prosthetic dentistry.

An increasing number of dental materials such as dental filling composites, enamel-dentin adhesives, fixation cements, and materials for inlays, veneers, crowns and bridges nowadays also for trays or dentures are based on visible-light curing materials. The visible-light curing materials show compared to thermal or chemical cured materials some benefits. Visible-light curing materials are usually single-components materials, which can be easily handled and are free of air bubbles. Furthermore, also highly viscous materials can be processed, used without waste and quickly cured by irradiation with visible-light of wavelengths between ca. 400 and 500 nm, depending on the used photoinitiator system (compare: L. A. Linden "Photocuring of Polymeric Dental Materials and Plastic Composite Resins" in J. P. Fouassier, J. F. Rabek (Ed.), Radiation Curing in Polymer Science and Technology, Elsevier Applied Science, London New York 1993, 387-466). Most of the visible-light curing dental materials are based on difunctional methacrylates, which show the drawback of a significant volume shrinkage during their polymerization.

One concept for low-shrinking materials is the ring-opening polymerization of cyclic monomers. In this context the ring-opening metathesis polymerization (ROP) of cyclic monomers is very attractive.

Dental materials which can be polymerized by ROMP are known in the prior art. EP 0796607 A2 discloses dental adhesives and coatings on the basis of functionalized polymers which are obtained by ring-opening metathesis polymerization of functionalized norbornene derivatives. ROMP is induced by transition metal carbene catalysts at 15 to 60 °C.

EP 0 796 607 A2 discloses dental materials on the basis of cyclic monomers or oligomers and polymers with cyclic groups, which can be cured by ROMP. ROMP can be induced by light.

EP 0 796 762 A2 discloses dental materials on the basis of oligomers and polymers which are obtained by ROMP of suitable norbornene monomers. The dental materials are hardened by radical polymerization.

US 6,455,029 reveals a composition for the use as a dental impression material including a polymerizable telechelic oligomer or polymer curable with a ruthenium carbene complex catalyst by ROMP.


Karlen et al., J. Polym. Sci. Part A, Polym. Chem. 33 (1995) 1665, and Hafner et al., Chimia 50 (1996) 131, investigated the ROPM of strained bicyclic olefins with cationic ruthenium complexes of the type [(η⁶-arene)Ru(η⁶-arene)R⁺] and [Ru (NC-R)₂]²⁺. The reaction was tolerant to a variety of functional groups and worked in protic polar solvents such as water, ethanol or ethanol/water. Irradiation was carried out with UV light.

Hafner et al., Angew. Chem. Int. Ed. Engl. 36 (1997) 2121 extended this work to [(η⁶-arene)RuCl₂PR₃] complexes and the corresponding osmium complexes. The ruthenium-based complexes (arene = p-cymene and PR₃ = PPh₃) were found to show higher reactivity for norborne polymerization than the osmium complexes.

WO 95/07310 discloses compositions on the basis of cyclic olefins which can be polymerized by photochemical ring-opening metathesis polymerization, using catalytic amounts of heat-stable ruthenium or osmium catalysts with at least one photolabile ligand. Irradiation times of up to 8 hours are needed to achieve complete hardening. Alternatively, short irradiation times of 5 to 60 seconds may be combined with heating to temperatures within the range of 50 to 200 °C.


It is the object of the present invention to provide polymerizable materials which show only a low volume shrinkage upon polymerization and which can be cured by visible light within a short time period at room temperature.

This object is achieved by polymerizable materials comprising:

(i) at least one ruthenium complex bearing at least one N-heterocyclic carbene ligand or precursors which generate a ruthenium complex bearing at least one N-heterocyclic carbene ligand in situ; and

(ii) at least one cyclic olefin capable of metathesis.

These materials are polymerizable by ring-opening metathesis polymerization. It was found that combining a ruthenium complex bearing at least one N-heterocyclic carbene ligand with cyclic olefins results in materials which can be hardened by short time irradiation with visible light without the need of subsequent thermal heating. These materials...
are therefore particularly useful as dental materials for intraoral use.

[0017] The materials of the present invention preferably comprise a ruthenium complex of the Formula (I)

\[
\begin{align*}
\text{R1} & \quad \text{R2} \\
\text{R3} & \quad \text{R4} \\
\text{R5} & \quad \text{R6} \\
\text{Ar} & \quad \text{R7} \\
\text{X1} & \quad \text{X2} \\
\text{X3} & \quad \text{X4}
\end{align*}
\]

Formula I

wherein:

- \(X_1\) and \(X_2\) are independently of each other Cl\(^-\), Br\(^-\) or a substituted or unsubstituted phenolate anion;
- \(R^1\) to \(R^6\) are independently of each other hydrogen, \(C_1\)-\(C_6\)-alkyl or COOR, \(R\) being \(C_1\)-\(C_3\)-alkyl;
- \(R^7\) and \(R^8\) are independently of each other hydrogen, \(C_1\)-\(C_{10}\)-alkyl, \(C_2\)-\(C_{10}\)-aryl, or halogen;
- \(Ar\) is \(C_2\)-\(C_{10}\)-cycloalkyl, substituted or unsubstituted phenyl, or substituted or unsubstituted aryl.

[0018] In this formula the dotted line indicates a single bond or, preferably, a double bond.

[0019] The optional substituents of the phenolate ion are preferably halogen, preferably chlorine and fluorine.

[0020] Preferred definitions of the variables which can be selected independently of each other are:

- \(X_1, X_2\) = independently of each other a fully or partially halogenated phenolate anion, in particular a pentafluorophenolate ion, more preferably Cl\(^-\);
- \(R^1\) to \(R^6\) = independently of each other hydrogen or \(C_1\)-\(C_3\)-alkyl, preferably methyl or isopropyl;
- \(R^7, R^8\) = independently of each other \(C_1\)-\(C_4\)-alkyl or, more preferably, hydrogen;
- \(Ar\) = a residue of the Formula (II)

\[
\begin{align*}
\text{R9} & \quad \text{R10} \\
\text{R11} & \quad \text{R12} \\
\text{R13} & \quad \text{R14}
\end{align*}
\]

Formula II

wherein

- \(R^6\), \(R^{10}\), \(R^{12}\) and \(R^{13}\) are independently of each other H or linear or branched \(C_1\)-\(C_{10}\)-alkyl, and
- \(R^{11}\) = H, linear or branched \(C_1\)-\(C_{10}\)-alkyl, preferably \(C_1\)-\(C_{2}\)-alkyl, halogen, \(C_1\)-\(C_{10}\)-alkoxy, preferably \(C_1\)-\(C_{2}\)-alkoxy, an amino group or a substituted or unsubstituted phenyl group, more preferably methyl.

[0021] The residues \(R^1\) to \(R^6\) may have the same or different meanings, preferably not more than three residues of \(R^1\) to \(R^6\) are COOR at the same time. It is further preferred that at least two residues of \(R^1\) to \(R^6\) are alkyl and the remaining residues are hydrogen. Most preferably \(R^1\) to \(R^6\) and the phenyl group to which they are bound form a hexamethylbenzene, durene (1,2,4,5-tetramethylbenzene), a mono- or dialkylbenzoate or most preferably a p-cymene (p-isopropyltoluene) ligand.

[0022] \(R^9\) to \(R^{13}\) are preferably not all H at the same time. More preferably \(R^9\) and \(R^{13}\) are \(C_1\)-\(C_{4}\)-alkyl, most preferably
methyl, and R₁⁰ and R₁² are H, and R₁¹ has one of the meanings given above with the exception of hydrogen.

[0023] The optional substituents of R₁² are preferably selected from the group consisting of C₁⁻C₄ alkyl, preferably C₁₋C₃ alkyl, phenyl, and phenyl substituted by C₁₋C₃-alkyl.

[0024] According to a particularly preferred embodiment Ar is 2,4,6-trimethylphenyl (mesityl, Mes). An imidazolidene residue substituted by two mesityl groups (R⁷ = R⁸ = H) is herein abbreviated as IMes.

[0025] Particularly preferred are complexes wherein all of the variables have one of the above defined preferred meanings.

[0026] Especially preferred is a complex according to Formula (I) wherein R¹, R², R⁴, R⁵, R² and R⁶ are hydrogen, R³ is methyl, R⁶ is isopropyl, X₁ and X₂ are Cl and Ar is a residue according to Formula (II) with R⁹, R₁¹ and R₁² are methyl and R₁⁰ and R₁² are H [RuCl₂(p-cymene) (IMes)].

[0027] It was found that complexes based on N-heterocyclic carbene (NHCs) substituted by alkyl groups on both nitrogen atoms showed considerably lesser catalytic activity in the polymerisation of strained olefins than the complexes according to the invention.

[0028] According to the invention the preferred catalysts for the visible-light induced ring-opening metathesis polymerization are ruthenium-arene complexes of type 4 bearing a stable N-heterocyclic carbene (NHC) ligand on the metal center. The heterocyclic ligands are substituted by aryl groups, which afford active catalysts, in particular if all the available ortho positions (2 and 6 positions) of the phenyl rings are blocked by alkyl groups, preferably, methyl groups. Biaryl substituted NHC ligands are advantageous, since it is believed that the presence of highly conjugated substituents on the NHC ligand favors the visible light absorption that triggers the photoinitiated polymerization process. Ligands, which are 2,4,6-trisubstituted aryl groups as defined above give particularly efficient catalysts. However, 2,3,(4),5-tetra or -pentaaryl substituted aryl groups also give efficient catalysts. In the case of 2,6-aryl substituted derivatives, a substitution in 4 position with a halogen or an alkyl group, or a substituted or unsubstituted aryl group is preferred.

[0029] Such species are preferably obtained by reacting e.g. the dichlororuthenium(p-cymene) dimer 1 with a stoichiometric amount of the free carbene. The carbene can be used in preformed form or can be generated in situ by deprotonation of a more stable ionic precursor. Particularly preferred precursors for the carbene are imidazolium and imidazolinium salts (2 or 3). In this formula Cl⁻ can be replaced by F⁻, Br⁻, I⁻ or BF₄⁻.

[0030] The synthesis of meta- or para-substituted 3,5-dimethylbiphenyl-4-ylamines can be carried out as described in the following.

[0031] Suitable biaryl amines are preferably constructed through a multi-step synthesis involving the ultrasound-promoted Suzuki cross-coupling of various meta- or para-substituted phenyl boronic acids with 4-bromo-2,6-dimethylaniline protected via its trifluoroacetamide. Subsequent deprotection with concentrated aqueous hydrochloric acid, followed by neutralization with barium hydroxide gives the meta- or para-substituted 3,5-dimethylbiphenyl-4-ylamines (5).

[0032] Furthermore, the imidazolium salts (3) bearing two biaryl moieties on the heterocyclic nitrogen atoms can be
obtained by condensation of glyoxal with two equivalents of biarylamine followed by cyclization with paraformaldehyde under acidic conditions. Moreover, the imidazolium salts (2) bearing two biaryl moieties on the heterocyclic nitrogen atoms, for example, the corresponding imidazolinium chlorides were constructed by reduction of dlimine into diamine dihydrochloride and then cyclization with triethyl orthoformate.

\[
\begin{align*}
H_2C=O + 2ArNH_2 & \xrightarrow{\text{PrOH, H}_2O} H_2C=N \rightarrow \left(\text{CH}_2\text{O}\right)_n \cdot \text{HCl} \\
\text{Ar} & \xrightarrow{i) \text{NaBH}_4 \atop ii) \text{HCl}} \text{HC(OEt)}_2 \cdot \Delta
\end{align*}
\]

[0033] These imidazol(ni)um chlorides can serve as ligand precursors for catalytic systems generated in situ. In that case, complexes of type 4 are formed in the reaction medium by mixing dichlororuthenium (p-cymene) dimer, an imidazol(ni)um salt, and a base.

[0034] Another way is to use imidazolium salts of type 3 and imidazolinium salts of type 2 for the synthesis of preformed ruthenium complexes of type 4. The imidazol(ni)um salts are first deprotonated in the presence of inorganic bases like sodium hydride, potassium tert-butoxide or potassium bis(trimethylsilyl)amide. The corresponding free NHs are isolated and react with e.g. [RuCl2(p-cymene)]2 to afford complexes of type 4 in the second discrete step.

[0035] An advantage of the catalyst precursors is their good air stability.

[0036] The cyclic olefins (ii) capable of metathesis can be mono- or polycyclic ring systems, for example having 2 to 5 rings, which are unsubstituted or substituted and can contain heteroatoms, for example N, O, Si, P or S, in one or more rings, and may be fused to aromatic or heteroaromatic rings. The cyclic rings preferably contain 4, 5 or 7 to 12, preferably 7 to 10 carbon atoms and 0 to 5, preferably 0, 1 or 2 heteroatoms.

[0037] In a preferred embodiment the cyclic olefin (ii) is a strained monocyclic olefin with 4, 5 or 7 to 12, preferably 7 to 10 carbon atoms. Preferred strained monocyclic olefins are cyclobutene, cyclopentene, cycloheptene or C9-C12-cycloalkenes.

[0038] In another preferred embodiment the cyclic olefin (ii) is a strained polycyclic ring system with at least one endocyclic double bond. Preferred strained polycyclic ring systems are polycyclic cycloolefins such as norbornene (bicyclo[2.2.1]heptene) or norbornene derivatives, in particular endo,exo-2,3-dicarboxynolbornene, endo,exo-2,3-dicarboxynolbornene, 5-norbornen-2-yl acetate and more preferably norbornene derivatives, according to the formulae III or IV.

![Formula III](image)

![Formula IV](image)
wherein:

A is O, S or a saturated or unsaturated C₁₋C₂₀-residue, containing 0-5 hetero atoms of the elements N, O, Si, P, S and 0-5 carbonyl groups;

R₁₄, R₁₅ are independently of each other H or a saturated or unsaturated C₁₋C₂₀-residue, containing 0-10 hetero atoms of the elements N, O, Si, P, S, F and 0-10 carbonyl groups; -COOR', -OR' or -SiR', R' being C₁₋C₃-alkyl or phenyl, or, together with the carbon atoms to which they are bound, form an alicyclic or aromatic, monocyclic or polycyclic residue with 4 to 12 carbon atoms;

n is 2 to 4;

B is a functional linking unit, such as O, S, -CO-O-, -CO-NH-or -O-CO-NH-, -Si(R')₂-, or -Si(R')(R'')₂-O-, R' being C₁₋C₃-alkyl, and

R₁₆ is n-times substituted C₁₋C₁₅-alkylene, C₄₋C₁₂-cycloalkylene, C₆₋C₁₄-arylene, C₇₋C₂₀-alkylenearylene, -Si(R'’’)(R’’’’), R’’’’ being C₁₋C₃-alkyl, or SiO₂.

[0039] The norbornene or norbornene derivative may be substituted by 1 or more, preferably 1 or 2 functional groups, which are preferably selected from the group consisting of ester, ether, halogen, alcohol, nitrile, unsubstituted, monosubstituted or disubstituted amide groups. Generally, ester groups with 2 to 5 carbon atoms, monosubstituted amide groups with 2 to 5 carbon atoms, disubstituted amide groups with 3 to 9 carbon atoms, and ether groups with 1 to 4 carbon atoms are preferred.

[0040] Particularly preferred monomers are:
For $B = -\text{Si}(\text{R}^1)_{2}-\text{O}$ and $\text{R}^{16} = \text{SiO}_2$ the strained polycyclic ring system is bound to silica to give a compound according to Formula V:

$$\begin{array}{c}
\text{A} \\
\text{Si} \\
\text{O} \\
(\text{SiO}_2)_x
\end{array}$$

Formula V

wherein

$r = 1$
$x = 1$ to 50, more preferably 20-50

and wherein A is preferably $-\text{CH}_3$.

Mixtures of different cyclic monomers as defined above can also be used.

In addition, the previous monomers can be mixed with comonomers (iii), preferably conventional mono- or difunctional (meth)acrylates, for example, methyl, ethyl, butyl, phenyl or benzyl (meth)acrylate, ethylene, diethylene or triethylene glycol di(meth)acrylate or 1,10-decandiol di(meth)acrylate.

The materials of the present invention preferably also comprise a filler (iv). Preferred fillers according to the invention are spherical inorganic fillers with a mean particle size of 5.0 to 800 nm, preferably of 20-300 nm, for example, fumed silica, precipitated silica, or mixed oxides from $\text{SiO}_2$, $\text{ZrO}_2$ and/or $\text{TiO}_2$ or other oxides, for example of the elements $\text{Ta}$, $\text{Yb}$, $\text{La}$ or $\text{Ce}$, as well as macro-fillers having a particle size of $0.4 \mu\text{m}$ to $10 \mu\text{m}$ or mini-fillers having a particles size of $5 \text{nm}$ to $100 \text{nm}$, such as quartz, glass ceramic or glass powder with an average particle size of 0.4 to $10 \mu\text{m}$, as well as X-ray-opaque fillers, such as ytterbium trifluoride. Glass or carbon fibres can also be used as fillers. Suitable reinforcing fibres are described, for example, in the "Taschenbuch der Kunststoff-Additive", R. Gächter, H. Müller, Carl Hanser Verlag, Munich and Vienna 1990, pages 617 to 662. Mixtures of different fillers can be used.

The composition according to the invention may contain further additives (v) such as stabilizers, UV absorbers,
dyestuffs, or pigments. In this context stabilizers are substances which prevent premature polymerization and thus above all increase the storage stability.

[0046] It is particularly preferred that the compositions of the present invention do not contain solvent. As used herein the term solvent refers to a chemical compound which is liquid at room temperature and serves only to control the reaction or to facilitate handling and processing of the composition, without still being present or necessary in the finished cured composition. If added at all, solvents are usually removed from the composition according to the present invention after polymerization thereof. Liquid reactive monomers which may or may not dissolve the catalyst or other components of the compositions and which are integrated in the polymer network upon polymerization are not solvents in this sense.

[0047] The materials according to this invention can be used for the preparation of polymerizable compositions for operative and prosthetic dentistry, for example, of filling composites, fixation cements or veneers.

[0048] Preferred materials according to the invention comprise:

0.001 to 5 wt.%, preferably 0.01 to 3 wt.%, and particularly preferably 0.1 to 1 wt.%, of a ruthenium complex (I) bearing N-heterocyclic carbene ligands either preformed or generated in situ;

1 to 90 wt.%, preferably 5 to 70 wt.%, and particularly preferably 10 to 50 wt.%, cyclic olefin (II) capable of metathesis;

0 to 50 wt.%, preferably 0 to 30 wt.%, and particularly preferably 0 to 20 wt.% co-monomer (III), preferably a mono- or difunctional methacrylate;

optionally 1 to 90 wt.%, preferably 10 to 80 wt.%, and particularly preferably 40 to 80 wt.% filler (IV);

0 to 2.0 wt.% additives (V).

[0049] Objects and advantages of the invention are further illustrated by the following examples. The particular materials and amounts thereof, as well as other conditions and details, cited in these examples should not be used to unduly limit the invention.

Examples

Example 1: 2,2,2-Trifluoro-N-(4'-tert-butyl-3,5-dimethylphenyl-4-yl)-acetamide

[0050] A two-neck 100 ml round bottom flask equipped with a reflux condenser capped with a three-way stopcock was charged with 4-tert-butylphenyboronic acid (0.841 g, 4.724 mmol), N-(4-bromo-2,6-dimethylphenyl)-2,2,2-trifluoroacacetamide (1.3236 g, 4.73 mmol), Pd(OAc)2 (45 mg, 0.2 mmol), and Na2CO3 (1.009 g, 9.35 mmol). The reactor was purged of air (three vacuum/argon cycles) before degassed methanol (50 ml) was added. The reaction flask was placed in an ultrasound bath for 4.5 h. The solution was filtered on celite and evaporated. The residue was dissolved in 20 ml of CHCl3 and washed twice with water. The organic layer was dried over MgSO4, filtered and evaporated. The crude product was recrystallized from a CHCl3/hexane mixture to afford 2,2,2-trifluoro-N-(4'-tert-butyl-3,5-dimethyl-bipheny-4-yl)-acetamide as a white grey solid in 74% yield. 1H NMR (CDCl3): δ = 1.36 (s, 9H, C(CH3)3); 2.28 (s, 6H, ortho-CH3); 7.30-7.31 (d, 2H, CHa); 7.44-7.50 (m, 4H, CHb).

Example 2: 4'-tert-Butyl-3,5-dimethyl-biphenyl-4-ylamine

[0051] A 250 ml round bottom flask was charged with 5.06 mmol (1.768 g) of 2,2,2-trifluoro-N-(4'-tert-butyl-3,5-dimethyl-biphenyl-4-yl)-acetamide, water (10 ml), and concentrated hydrochloric acid (10 ml). The mixture was heated to reflux for 17 h. The solution was allowed to cool to ambient temperature before it was evaporated to dryness. The residue was refluxed with Ba(OH)2·8 H2O (9 g) in 100 ml of water for 1.5 h and then cooled to room temperature. This aqueous solution was extracted three times with 20 ml of CHCl3. The organic layer was dried over MgSO4, filtered, evaporated and dried under vacuum. The resulting brown precipitate of 4'-tert-butyl-3,5-dimethyl-biphenyl-4-ylamine was obtained in 69% yield. 1H NMR (CDCl3): δ = 1.37 (s, 9H, C(CH3)3); 2.27 (s, 6H, ortho-CH3); 7.30-7.31 (d, 2H, CHa); 7.44-7.50 (m, 4H, CHb); 13C NMR (CDCl3): δ = 18.3 (ortho-CH3); 31.4 (CH3); 34.6 (C(CH3)3); 125.8 (CHa); 126.8 (CHb); 127.2 (CHb); 135.6 (CHa); 137.3 (CHb); 141.4 (CHa); 150.7 (CHb).

Example 3: Glyoxal-bis(4'-tert-butyl-3,5-dimethylphenyl)limine

[0052] A mixture of glyoxal (0.307 g of a 40% aqueous solution) in 5 ml of 2-propanol and 2.5 ml of water was slowly added to 4'-tert-butyl-3,5-dimethyl-biphenyl-4-ylamine (1.1 g, 4.34 mmol) in 15 ml of 2-propanol. The reaction mixture was stirred for 3 days at room temperature. The resulting suspension was filtered with suction and the precipitate was rinsed with water (5 ml). It was dried under an IR lamp. The glyoxal-bis(4'-tert-butyl-3,5-dimethylphenyl)limine was obtained as a yellow powder in 71% yield. 1H NMR (CDCl3): δ = 1.37 (s, 18H, C(CH3)3); 2.26 (s, 12H, ortho-CH3); 7.33 (s, 4H, CHa); 7.45-7.47 (d, 4H, CHb); 7.53-7.55 (d, 4H, CHb); 8.19 (s, 2H, CH=N); 13C NMR (CDCl3): δ = 18.6 (ortho-CH3);
Example 4: N,N'-Bis(4'-tert-butyl-3,5-dimethyl-biphenyl-4-yl)-ethane-1,2-diamine dihydrochloride

[0053] A solution of glyoxal-bis(4'-tert-butyl-3,5-dimethylbiphenyl)imine (572 mg, 1.08 mmol) in 25 ml of THF was cooled to 0°C before 188 mg of sodium borohydride (4.42 mmol) were added in one portion. Then 2 eq. (0.178 ml) of concentrated HCl were added dropwise. The reaction mixture was stirred at 0°C for 20 min. A 3 M aqueous solution of HCl (40 ml) was then carefully added to the flask, still at 0°C, and the reaction mixture was stirred for 1 h at room temperature. The resulting suspension was filtered with suction and the precipitate was rinsed with a small quantity of water and dried under vacuum. N,N'-Bis(4'-tert-butyl-3,5-dimethyl-biphenyl-4-yl)-ethane-1,2-diamine dihydrochloride was obtained as white yellowish powder in 66% yield. 1H NMR (DMSO-d6): δ = 1.31 (s, 18H, C(CH3)3); 2.57 (s, 12H, CH3); 3.76 (s, 4H, CH2); 7.44-7.48 (d, 8H, CHar); 7.58-7.60 (d, 4H, CHar). 13C NMR (DMSO-d6): δ = 18.4 (ortho-CH3); 31.0 (CH3); 34.1 (C(CH3)3); 42.2 (CH2); 125.8 (CHar); 135.5 (CHar); 136.1 (CHar); 138.6 (CHar); 150.0 (CHar).

Example 5: 1,3-Di(4'-tert-butyl-3,5-dimethylbiphenyl)-imidazolium chloride

[0054] A N,N'-diaryl ethylene diamine dihydrochloride (1.872 g, 3.09 mmol) was suspended in 50 ml of triethylorthoformate containing 2 drops of fumic acid. The mixture was refluxed for two days in an oil bath at 130°C. It was then cooled to 8°C and the resulting suspension was filtered with suction. The precipitate was rinsed with small portions of Et2O and dried under vacuum. The 1,3-di(4'-tert-butyl-3,5-dimethylbiphenyl)imidazolium chloride was obtained as a white powder in 60% yield. 1H NMR (CDCl3): δ = 1.30 (s, 18H, C(CH3)3); 2.22 (s, 12H, ortho-CH2); 3.82 (s, 4H, CH2); 7.21-7.42 (m, 6H, CHar); 7.95 (s, 1H, im-H²).

Example 6: 1,3-Di(4'-tert-butyl-3,5-dimethylbiphenyl)-imidazolium chloride

[0055] A two-neck 25 ml round bottom flask equipped with a magnetic stirring bar and capped with a three-way stopcock was charged with paraformaldehyde (146 mg, 4.89 mmol). The reactor was purged of air (three vacuum/argon cycles) before 1.44 ml of 4 N solution of HCl in dioxane was added. The mixture was stirred and gently warmed until complete dissolution of the solid. A second two-neck 25 ml round bottom flask equipped with a magnetic stirring bar and capped with a three-way stopcock was charged with glyoxal-bis(4'-tert-butyl-3,5-dimethylbiphenyl)imine (2.158 g, 4.08 mmol) and purged of air (three vacuum/argon cycles) before 16 ml of dry THF was added. The two mixtures were cooled at 0°C in an ice-water bath and the acidic paraformaldehyde solution was added dropwise to the dimine solution. A precipitate appeared within 1 h. The resulting suspension was stirred 4 h at room temperature. It was filtered with suction and the precipitate was rinsed with AcOEI and dried under vacuum. The 1,3-di(4'-tert-butyl-3,5-dimethylbiphenyl)imidazolium chloride was obtained as a white grey powder in 65% yield. 1H NMR (DMSO-d6): δ = 1.34 (s, 18H, C(CH3)3); 2.27 (s, 12H, ortho-CH2); 7.53-7.55 (d, 4H, CHar); 7.69-7.70 (m, 8H, CHar); 8.40 (s, 2H, CH=NC); 9.87 (s, 1H, im-H²). 13C NMR (DMSO-d6): δ = 17.3 (ortho-CH3); 31.1 (CH3); 34.4 (C(CH3)3); 42.2 (CH2); 125.6 (CHar); 135.5 (CHar); 136.1 (CHar); 138.6 (CHar); 150.0 (CHar).

Example 7: RuCl2(p-cymene)-(N,N'-di(4'-tert-butyl-3,5-dimethylbiphenyl))-imidazol-2-ylidene

[0056] A two-neck 100 ml round bottom flask equipped with a magnetic stirring bar and capped with a three-way stopcock was charged with 1.8658 mmol (1.075 g) of 1,3-di(4'-tert-butyl-biphenyl)imidazolium chloride and 1.8558 mmol (370 mg) of potassium bis(trimethylsilylamide) in a glovebox. Next 20 ml of dry and degassed THF was added under an argon atmosphere. The reaction mixture was stirred for 20 min at room temperature before the solvent was evaporated under vacuum. Crude N,N'-di(4'-tert-butyl-3,5-dimethylbiphenyl)imidazol-2-ylidene was obtained as a brown precipitate in 88% yield. A mixture of [RuCl2(p-cymene)]2 (0.815 mmol, 499 mg) and 25 ml of dry THF was added to the crude residue under an argon atmosphere. The reaction mixture was stirred for 1.5 h at room temperature before the solvent was evaporated under vacuum in the darkness. RuCl2(p-cymene)-(N,N'-di(4'-tert-butyl-3,5-dimethylbiphenyl))imidazol-2-ylidene was obtained as a brown-red solid in 89% yield. 1H NMR (CDCl3): δ = 1.25 (s, 6H, (CH3)2CH); 1.30 (s, 18H, C(CH3)3); 2.13 (s, 3H, CH3); 2.30 (s, 12H, ortho-CH2); 2.80-3.00 (m, 1H, CH(CH3)3); 3.87 (s, 4H, CH2); 5.32-5.45 (s, 2H, CHar); 5.53-5.62 (s, 2H, CHar); 7.09-7.47 (m, 12H, CHar).

Example 8: ROMP of norbornene using a visible-light lamp

[0057] Norbornene (361 mg, 3.834 mmol) was dissolved in 5 ml of PhCl, next 7.51x10⁻⁶ mol (4.6 mg) of [RuCl2(p-cymene)]2, 1.525x10⁻² mmol (5.2 mg) of 1,3-dimesitylimidazolium chloride and 3.03x10⁻² mmol (3.4 mg) of
KOTBu were added. The solution was irradiated with high power program (1200 mW/cm²) of blue light emitting Astralis 10 lamp for 120 s. 10 ml of CHCl₃ were added to dissolve the reaction mixture and the chloroform solution was slowly added to 500 ml of MeOH to precipitate the polymer. The white polymer was filtered and dried under vacuum. Yield 92%.

Example 9: ROMP of neat endo,exo-2,3-dicarboethoxy-norbornene using a visible-light lamp

[0059] Endo,exo-2,3-dicarboethoxy-norbornene (477 mg, 2 mmol) and 8x10⁻⁶ mol (4.9 mg) of [RuCl₂(p-cymene)](IMes) were placed in an open 10 ml glass vial. The reaction mixture was homogenized in an ultrasound bath (5 min at room temperature). The solution was irradiated with high power program of blue light emitting Astralis 10 lamp (1200 mW/cm²) for 120 s. 10 ml of CHCl₃ were added to dissolve the reaction mixture and the chloroform solution was slowly added to 500 ml of MeOH to precipitate the polymer. The white polymer was filtered and dried under vacuum. Yield 56%.

Example 10: ROMP of neat 5-norbornen-2-yl acetate using a visible-light lamp

[0060] 5-Norbornen-2-yl acetate (304.4 mg, 2 mmol) and 1.002x10⁻⁶ mol (0.6 mg) of [RuCl₂(p-cymene)](IMes) were placed in an open 10 ml glass vial. The catalyst was well soluble in the monomer. The solution was irradiated with high power program (1200 mW/cmm²) of blue light emitting Astralis 10 lamp for 120 s. The reaction mixture became solid during the irradiation time. 10 ml of CHCl₃ were added to dissolve the reaction mixture and the chloroform solution was slowly added to 500 ml of MeOH to precipitate the polymer. The white polymer was filtered and dried under vacuum. Yield 99%.

Example 11: ROMP of neat 5-norbornen-2-yl acetate in presence of TEGDMA using a visible-light lamp

[0061] 5-Norbornen-2-yl acetate (608 mg, 4 mmol), triethylene glycol dimethacrylate (TEGDMA) (6 mg, 2x10⁻⁷ mmol) and 2x10⁻⁶ mol (1.2 mg) of [RuCl₂(p-cymene)](IMes) were placed in an open 10 ml glass vial. A reaction mixture remained liquid for about 10 min in day light. The solution was irradiated with high power program (1200 mW/cmm²) of blue light emitting Astralis 10 lamp for 120 s. The reaction mixture became solid during the irradiation time. 10 ml of CHCl₃ were added to dissolve the reaction mixture and the chloroform solution was slowly added to 500 ml of MeOH to precipitate the polymer. The white polymer was filtered and dried under vacuum. Yield 99%.

Example 12: ROMP of neat 5-norbornen-2-yl acetate using a Plasma lamp

[0062] 5-Norbornen-2-yl acetate (304.4 mg, 2 mmol) and 1.002x10⁻⁶ mol (0.6 mg) of [RuCl₂(p-cymene)](IMes) were placed in an open 10 ml glass vial. The catalyst was well soluble in the monomer. The solution was irradiated with a Plasma lamp (xenon arc plasma lamp) for 120 s. 10 ml of CHCl₃ were added to dissolve the reaction mixture and the chloroform solution was slowly added to 500 ml of MeOH to precipitate the polymer. The white polymer was filtered and dried under vacuum. Yield 74%.

Example 13: Preparation of composite

[0063] 5-Norbornen-2-yl acetate (4g, 2.63x10⁻² mol) and 1.29x10⁻² mmol (7.88 mg) of [RuCl₂(p-cymene)](IMes)] were well stirred. Then 6 g of filler mixture containing YbF₃ and fumed silica OX-50wsil (with YbF₃/OX-50wsil = 1.87 g/4.13 g) was added to the reaction mixture. The reaction mixture was stirred for 20 s in a stirring machine. The resin was placed in a mould and irradiated using Spectramat lamp (400W metal halogen bulb, 400-500 nm wavelength range) 4x3min on both sides. The resulting material had a grey-brown shade and an elastic modulus of 3550 N/mm². The elastic modulus was determined according to the ISO norm 4049.

Example 14: ROMP of neat endo,exo-2,3-dicarbomethoxy-norbornene using an Astralis 7 lamp:

[0064] Endo,exo-2,3-dicarbomethoxy-norbornene (420.4 mg, 2 mmol) was placed in an open 10 ml glass vial and slightly heated with a heat gun until it became liquid. [RuCl₂(p-cymene)](IMes)] (0.6 mg, 1.002x10⁻⁶ mol) was then added. The complex was well soluble in the monomer. The solution was irradiated with high power program of blue light emitting Astralis 7 lamp (750 mW/cm²) for 120 s. The resulting solid material had a brownish tint. 10 ml of CHCl₃ were added.
and the chloroform solution was slowly poured into 500 ml of MeOH to precipitate the polymer. The white polymer was filtered and dried under vacuum. Yield 60%.

Example 15 (comparative): ROMP of neat 5-norbornen-2-yl acetate using Astralis 7 lamp and [RuCl₂(p-cymene)PCy₃] as catalyst precursor:

[0065] 5-Norbornen-2-yl acetate (304.4 mg, 2 mmol) and [RuCl₂(p-cymene)PCy₃] (0.6 mg, 1.002x10⁻⁶ mol; Cy = cyclohexyl) were placed in an open 10 ml glass vial. The catalyst was well soluble in the monomer. The solution was irradiated with high power program (750 mW/cm²) of blue light emitting Astralis 7 lamp for 120 s. The resulting material had a brownish-orange tint. 10 ml of CHCl₃ were added to the resulting liquid material and the chloroform solution was slowly poured into 500 ml of MeOH to precipitate the polymer. The white polymer was filtered and dried under vacuum. Yield 11%.

[0066] The phosphorus-based complex [RuCl₂(p-cymene)PCy₃] had been used by Hafner et al., Angew. Chem. Int. Ed. Engl. 1997, for ROMP reactions of norbornene in toluene. The present examples shows that this complex is not suitable for ROMP in the absence of solvent while complexes with N-heterocyclic carbene ligands are highly active (cf. Example 10).

Example 16 (comparative): ROMP of neat endo,exo-2,3-dicarbomethoxynorbornene using an Astralis 7 lamp and [RuCl₂(p-cymene)PCy₃] as catalyst precursor:

[0067] *Endo,exo*-2,3-dicarbomethoxynorbornene (420.4 mg, 2 mmol) was placed in an open 10 ml glass vial and slightly heated with a heat gun until it became liquid. [RuCl₂(p-cymene)PCy₃] (0.6 mg, 1.002x10⁻⁶ mol) was then added. The complex was well soluble in the monomer. The solution was irradiated with high power program of blue light emitting Astralis 7 lamp (750 mW/cm²) for 120 s. The resulting liquid had an orange tint. After 17 h, the liquid reaction mixture was slowly poured into 500 ml of MeOH but no polymer precipitated. Yield 0%.

[0068] In this example [RuCl₂(p-cymene)PCy₃] was completely inactive while the corresponding N-heterocyclic carbene complex [RuCl₂(p-cymene)(IMes)] resulted in a polymerization yield of 60% when tested under identical conditions (Example 14).

Example 17 (comparative): ROMP of neat endo,exo-2,3-dicarboethoxynorbornene using an Astralis 7 lamp and [RuCl₂(p-cymene)PCy₃] as catalyst precursor:

[0069] *Endo,exo*-2,3-dicarboethoxynorbornene (476 mg, 2 mmol) and [RuCl₂(p-cymene)PCy₃] (0.6 mg, 1.002x10⁻⁶ mol) were placed in an open 10 ml glass vial. The catalyst was well soluble in the monomer. The solution was irradiated with high power program of blue light emitting Astralis 7 lamp (750 mW/cm²) for 120 s. The resulting liquid had an orange tint. After 17 h, the liquid reaction mixture was slowly poured into 500 ml of MeOH but no polymer precipitated. Yield 0%.

[0070] In this example a different monomer was used than in Example 16. However, still no polymerization could be observed.

Example 18 (comparative): ROMP of neat *endo,exo*-2,3-dicarbomethoxynorbornene using an Astralis 7 lamp and [Ru(CH₂CN)₆](tos)₂ as catalyst precursor:

[0071] *Endo,exo*-2,3-dicarbomethoxynorbornene (420.4 mg, 2 mmol) was placed in an open 10 ml glass vial and slightly heated with a heat gun until it became liquid. [Ru(CH₂CN)₆](tos)₂ (0.7 mg, 1.002x10⁻⁶ mol; tos = p-toluenesulfonate) was then added. The complex was not soluble in the monomer. The mixture was sonicated in an ultrasound bath for 1 h but no sign of dissolution was observed. The mixture was then irradiated with high power program of blue light emitting Astralis 7 lamp (750 mW/cm²) for 120 s. After 2 h, the resulting liquid material was slowly poured into 500 ml of MeOH but no polymer precipitated. Yield 0%.

[0072] The ruthenium complex [Ru(CH₂CN)₆](tos)₂ was found by Mühlbech and coworkers, Journal of Polymer Science: Part A: Polymer Chemistry, Vol. 33, 1665-1674 (1995), to be highly active in the photo-induced ROMP of strained bicylic olefins in protic polar solvents such as water, ethanol or ethanol/water. The reactions had been initiated by irradiation with a Hg lamp for 15 min. The present example shows that [Ru(CH₂CN)₆](tos)₂ completely failed to initiate polymerization upon irradiation with a dental light source in the absence of solvent. Furthermore, Mühlbech et al. performed the polymerization under argon, i.e. under conditions which are disadvantageous for dental purposes.

Example 19 (comparative): ROMP of neat 5-norbornen-2-yl acetate using an Astralis 7 lamp and
EP 1 614 410 A1

[Ru(CH₂CN)₆](tos)₂ as catalyst precursor:

[0073] 5-Norbornen-2-yl acetate (304.4 mg, 2 mmol) and [Ru(CH₂CN)₆](tos)₂ (0.7 mg, 1.002x10⁻⁶ mol) were placed in an open 10 ml glass vial. The catalyst was not soluble in the monomer. The mixture was sonicated in an ultrasound bath for 1 h but no sign of dissolution was observed. The mixture was then irradiated with high power program (750mW/cm²) of blue light emitting Astralis 7 lamp for 120 s. After 2 h the resulting liquid material was slowly poured into 500 ml of MeOH but no polymer precipitated. Yield 0%. In this example a different monomer was used than in Example 19. However, still no polymerization could be observed.

Example 20 (comparative): ROMP of cyclooctene using [Ru(CH₂CN)₆](tos)₂ as catalyst precursor:

[0074] A one-neck 25 ml round bottom flask equipped with a magnetic stirring bar and capped with a three-way stopcock was charged with 7.5x10⁻⁶ mol (5 mg) of [Ru(CH₂CN)₆](tos)₂. The reactor was purged of air (three vacuum/argon cycles) before dry chlorobenzene (1.25 ml) was added. The solution was warmed to 60 °C in a thermostated oil bath and irradiated by a 40W *cold white* fluorescent tube placed 10 cm away from the Pyrex reaction flask. The catalyst was not soluble in the reaction medium. Cyclooctene (0.25 ml, 0.24 g) was added via syringe. The reaction mixture was stirred for 2 h at 60 °C. The resulting liquid material was slowly poured into 500 ml of MeOH but no polymer precipitated. Yield 0%.

[0075] In this example cyclooctene was used as monomer but the initiator remained inactive.

Claims

1. A dental material being polymerizable by ring-opening metathesis polymerization comprising

   (i) at least one ruthenium complex bearing at least one N-heterocyclic carbene ligand or precursors which generate a ruthenium complex bearing at least one N-heterocyclic carbene ligand in situ; and

   (ii) at least one cyclic olefin capable of metathesis.

2. The material of claim 1 wherein the ruthenium complex is of the formula

   ![Formula I](image)

   wherein:

   X₁ and X₂ are independently of each other Cl⁻, Br⁻ or a substituted or unsubstituted phenolate anion;

   R¹ to R⁶ are independently of each other hydrogen, C₁-C₆ alkyl or COOR, R being C₁-C₂ alkyl;

   R⁷ and R⁸ are independently of each other hydrogen, C₁-C₁₀ alkyl, C₆-C₁₀ aryl, or halogen;

   Ar is C₆-C₁₀ cycloalkyl, substituted or unsubstituted phenyl, or substituted or unsubstituted aryl, and the dotted line indicates a single bond or a double bond.

3. The material of claim 2 wherein the variables are:

   X₁, X₂ = independently of each other a fully or partially halogenated phenolate anion, in particular a pentafluorophenolate ion, preferably Cl⁻;

   R¹ to R⁶ = independently of each other hydrogen or C₁-C₆ alkyl, preferably methyl or isopropyl;

   R⁷, R⁸ = independently of each other C₁-C₄ alkyl, preferably hydrogen;

   Ar = a residue of the Formula (II)
wherein
R⁹, R¹⁰, R¹² and R¹³ are independently of each other H or linear or branched C₁-C₁₀-alkyl, and
R¹¹ is H, linear or branched C₁-C₁₀-alkyl, preferably C₁-C₃-alkyl, halogen, C₁-C₁₀-alkoxy, preferably
C₁-C₂-alkoxy, an amino group or a substituted or unsubstituted phenyl group.

4. The material of claim 3 wherein the substituents of R¹¹ are selected from the group consisting of C₁-C₁₀ alkyl, phenyl, phenyl substituted by C₁-C₃ alkyl.

5. The material of any one of the preceding claims comprising [RuCl₂(p-cymene)]₂ and an imidazolium salt or imida-
zolium base as the precursors of the catalyst.

6. The material of claim 5 wherein the imidazolium salt is of the formula

wherein Ar is defined as above and Y⁻ is F⁻, Cl⁻, Br⁻, I⁻ or BF₄⁻.

7. The material of claim 5 wherein the imidazolinium salt is of the formula

wherein Ar is defined as above and Y⁻ is F⁻, Cl⁻, Br⁻, I⁻ or BF₄⁻.

8. The material of any one of the preceding claims wherein the cyclic olefin capable of metathesis is a monocyclic ring
or a polycyclic ring system having 2 to 5 rings, which are unsubstituted or substituted, can contain one or more
heteroatoms from the group consisting of N, O, S, P or S, in one or more rings, and can contain fused aromatic or
heteraromatic rings.

9. The material of claim 8, wherein the cyclic rings contain 4, 5 or 7 to 12, preferably 7 to 10 carbon atoms and 0 to 5,
preferably 0, 1 or 2 heteroatoms.

10. The material of claim 9 wherein the cyclic olefin is a strained monocyclic olefin with 4, 5 or 7 to 12 carbon atoms.
11. The material of claim 9 wherein the cyclic olefin is a strained polycyclic ring system with at least one endocyclic double bond.

12. The material of claim 11 wherein the polycyclic olefin is norbornene (bicyclo[2.2.1]heptene), endo,exo-2,3-dicarboethoxynorbornene, endo,exo-2,3-dicarboxomethoxynorbornene, 5-norbornen-2-yl acetate, a norbornene derivative according to formula III or IV

\[
\text{Formula III}
\]

\[
\text{Formula IV}
\]

wherein:

A is O, S or a saturated or unsaturated C_1-C_{20}-residue, containing 0-5 hetero atoms of the elements N, O, Si, P, S and 0-5 carbonyl groups;

\(R_{14}, R_{15}\) are independently of each other H or a saturated or unsaturated C_1-C_{20}-residue, containing 0-10 hetero atoms of the elements N, O, Si, P, S, F and 0-10 carbonyl groups; -COOR', -OR', -SiR', R' being C_1-C_3-alkyl or phenyl, or, together with the carbon atoms to which they are bound, form an alicyclic or aromatic, monocyclic or polycyclic residue with 4 to 12 carbon atoms;

\(n\) is 2 to 4;

B is a functional linking unit, such as O, S, -CO-O-, -CO-NH- or -O-CO-NH-, -Si(R')_2-, or -Si(R')_2-O-, R' being C_1-C_3-alkyl, and

\(R_{16}\) is \(n\)-times substituted C_1-C_{15}-alkylene, C_2-C_{12}-cycloalkylene, C_6-C_{14}-arylene, C_7-C_{20}-alkylenearylene, -Si(R'')_4-n', R'' being C_1-C_3-alkyl, or SiO_2.

13. The material of claim 12 wherein the norbornene or norbornene derivative is substituted by 1 or more functional groups, which are selected from the group consisting of ester, ether, halogen, alcohol, nitrile, unsubstituted, monosubstituted or disubstituted amide groups.

14. The material of any of the preceding claims further comprising at least one co-monomer (iii).

15. The material of claim 14, wherein the co-monomer (iii) is selected from the group consisting of mono- or difunctional (meth)acrylates, preferably, methyl, ethyl, butyl, phenyl or benzyl (meth)acrylate, ethylene, diethylene or triethylene glycol di((meth)acrylate and 1,10-decanediol di((meth)acrylate).

16. The material of any one of the preceding claims further comprising (iv) filler.

17. The material of claim 16 wherein the filler is a particulate material of spherical inorganic particles with a mean particle size of 5.0 bis 800 nm, a macro-filler with an average particle size of 0.4 to 10 \(\mu\)m and/or a mini-filler with an average particles size of 5 to 100 nm.

18. The materials of claim 16 or 17 wherein the filler is selected from the group consisting of fumed silica, precipitated silica, mixed oxides from SiO_2, ZrO_2 and/or TiO_2 or other oxides, quartz powder, glass ceramic powder, glass powder, ytterbium trifluoride and mixtures thereof.

19. The material of any one of claims 16 to 18 comprising glass fibers and/or carbon fibers as a filler.

20. The material of any one of the preceding claims further comprising one or more additives (v) selected from the group consisting of stabilizers, UV absorbers, dyestuffs, pigments and mixtures thereof.
21. The material of any one of the preceding claims comprising
   0.001 to 5 wt.-% ruthenium complex (i);
   1 to 90 wt.-% cyclic olefin (ii) capable of metathesis;
   0 to 50 wt.% co-monomer (iii);
   optionally 1 to 90 wt.-% filler (iv); and
   0 to 2.0 wt.-% additives (v).

22. The material of any one of the preceding claims which is substantially free of solvent.

23. Use of the material of any one of the preceding claims as a dental material or for the manufacture of a dental material.

24. The use of claim 23 wherein the dental material is a material for operative and prosthetic dentistry.

25. The use of claim 23 wherein the material is a filling composite, a fixation cement or a veneering material.
# DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document with indication, where appropriate, of relevant passages</th>
<th>Relevant to claim</th>
<th>CLASSIFICATION OF THE APPLICATION (IN Cl./7)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Y</td>
<td>EP 1 025 830 A (IVOCLAR AG) 9 August 2000 (2000-08-09) * the whole document *</td>
<td>1-25</td>
<td></td>
</tr>
</tbody>
</table>

**TECHNICAL FIELDS SEARCHED**

( int.Cl./7 )

A61K
C08G
ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO. EP 04 10 3088

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on 18-11-2004. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>CN 1439354 A</td>
<td>03-09-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2003192520 A</td>
<td>09-07-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1318162 A2</td>
<td>11-06-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2003212973 A</td>
<td>30-07-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2003166461 A</td>
<td>04-09-2003</td>
</tr>
<tr>
<td>EP 1025830 A</td>
<td>09-08-2000</td>
<td>DE 19905093 A1</td>
<td>03-08-2000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2297442 A1</td>
<td>01-08-2000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1025830 A2</td>
<td>09-08-2000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2000226306 A</td>
<td>15-08-2000</td>
</tr>
</tbody>
</table>

For more details about this annex see Official Journal of the European Patent Office, No. 12/02